• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

加拿大国家药物保险计划的公私合作替代方案。

Public-private partnership alternative for a national pharmacare program in Canada.

作者信息

Nauenberg Eric, Yurga Emre

机构信息

Institute for Health Policy, Management and Evaluation, University of Toronto, Toronto, Canada.

Canadian Centre for Health Economics, University of Toronto, Toronto, Canada.

出版信息

J Pharm Policy Pract. 2023 Feb 6;16(1):21. doi: 10.1186/s40545-023-00526-3.

DOI:10.1186/s40545-023-00526-3
PMID:36747233
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9903457/
Abstract

BACKGROUND

Recently, the government and an opposition party cut a deal that involved a promise to consider implementing a single-payer pharmacare scheme in Canada in exchange for supporting the current minority government. There have been political headwinds from the private extended health insurance industry, the provinces of Ontario and Quebec, as well as the pharmaceutical industry. We suggest a new multiple-payer of mixed-resort framework that achieves both the goal of universal coverage and preserves the private extended health insurance industry through a scheme based on the current coordination of benefits between private payers in this sector.

METHODS

We employ game theory to better understand the dynamics within a market that involves multiple payers. In particular, we use the game of Collective Action to help illustrate the problems of free-ridership.

RESULTS

An analysis of the dynamics of this market suggests that ex-ante agreements need to be struck between all payers in a multi-payer marketplace to achieve both stability and sustainability of such a framework.

CONCLUSION

We show that universal coverage is still possible while leveraging the existing system of private extended health insurance so long as a well-established system for coordinating benefits between public and private payers is established. A stable public/private partnership can achieve universal coverage so long as a system for coordinating benefits is instituted. The proposed alternative will achieve the same goals, but maintain a niche for the private sector thereby maintaining therapeutic variety in the marketplace.

摘要

背景

最近,加拿大政府与一个反对党达成了一项协议,其中包括承诺考虑在加拿大实施单一支付者药物保险计划,以换取对现任少数党政府的支持。这一举措面临来自私人扩展医疗保险行业、安大略省和魁北克省以及制药行业的政治阻力。我们提出了一种新的混合支付框架,通过基于该行业当前私人支付者之间的福利协调计划,既能实现全民覆盖的目标,又能保留私人扩展医疗保险行业。

方法

我们运用博弈论来更好地理解涉及多个支付者的市场动态。特别是,我们使用集体行动博弈来帮助说明搭便车问题。

结果

对该市场动态的分析表明,在多支付者市场中,所有支付者之间需要达成事前协议,以实现这种框架的稳定性和可持续性。

结论

我们表明,只要建立一个完善的公共和私人支付者之间的福利协调系统,在利用现有私人扩展医疗保险系统的同时,全民覆盖仍然是可能的。只要建立一个福利协调系统,稳定的公私伙伴关系就能实现全民覆盖。提议的替代方案将实现相同的目标,但为私营部门保留一个利基市场,从而保持市场上的治疗多样性。

相似文献

1
Public-private partnership alternative for a national pharmacare program in Canada.加拿大国家药物保险计划的公私合作替代方案。
J Pharm Policy Pract. 2023 Feb 6;16(1):21. doi: 10.1186/s40545-023-00526-3.
2
Prescription drug coverage in Canada: a review of the economic, policy and political considerations for universal pharmacare.加拿大的处方药保险范围:对全民药物保险的经济、政策和政治考量的综述
J Pharm Policy Pract. 2018 Nov 7;11:28. doi: 10.1186/s40545-018-0154-x. eCollection 2018.
3
The role of insurance in the achievement of universal coverage within a developing country context: South Africa as a case study.发展中国家实现全民覆盖背景下的保险作用:以南非为例。
BMC Public Health. 2012;12 Suppl 1(Suppl 1):S5. doi: 10.1186/1471-2458-12-S1-S5. Epub 2012 Jun 22.
4
Long-term care financing: lessons from France.长期护理融资:法国的经验教训。
Milbank Q. 2015 Jun;93(2):359-91. doi: 10.1111/1468-0009.12125.
5
Estimated cost of universal public coverage of prescription drugs in Canada.加拿大全民公共处方药保险的估计成本。
CMAJ. 2015 Apr 21;187(7):491-497. doi: 10.1503/cmaj.141564. Epub 2015 Mar 16.
6
The value and consequences of using public health technology assessments for private payer decision-making in Canada: one size does not fit all.在加拿大,将公共卫生技术评估用于私人支付方决策的价值及后果:一刀切并不适用。
J Med Econ. 2019 May;22(5):478-487. doi: 10.1080/13696998.2019.1582535. Epub 2019 Mar 4.
7
Post-Romanow pharmacare: last-dollar first...first-dollar lost?后罗曼诺医保:最后一美元优先……第一美元流失?
Healthc Pap. 2004;4(3):10-20. doi: 10.12927/hcpap..16871.
8
What can the Canadians and Americans learn from each other's health care systems?加拿大人和美国人可以从彼此的医疗保健系统中学到什么?
Int J Health Plann Manage. 2016 Jul;31(3):349-70. doi: 10.1002/hpm.2374. Epub 2016 Jul 29.
9
Universal New York Health Care. A single-payer strategy linking cost control and universal access.纽约全民医疗保健。一种将成本控制与全民医保相联系的单一支付者策略。
N Engl J Med. 1990 Sep 6;323(10):640-4. doi: 10.1056/NEJM199009063231005.
10
After More Than 50 Years, Pharmacare (and Dental Care) are Coming to Canada.五十多年后,加拿大将迎来医药保健(和牙科保健)。
Int J Health Serv. 2022 Jul;52(3):341-346. doi: 10.1177/00207314221100654. Epub 2022 May 9.

本文引用的文献

1
The impact of OHIP+ pharmacare on use and costs of public drug plans among children and youth in Ontario: a time-series analysis.安大略省 OHIP+ 药品福利计划对儿童和青少年公共药品计划使用和成本的影响:时间序列分析。
CMAJ Open. 2022 Sep 27;10(3):E848-E855. doi: 10.9778/cmajo.20210295. Print 2022 Sep-Oct.
2
Cost-related medication nonadherence in Canada: a systematic review of prevalence, predictors, and clinical impact.加拿大与费用相关的药物治疗不依从性:患病率、预测因素及临床影响的系统评价
Syst Rev. 2021 Jan 6;10(1):11. doi: 10.1186/s13643-020-01558-5.
3
The consequences of patient charges for prescription drugs in Canada: a cross-sectional survey.加拿大处方药患者付费的后果:一项横断面调查。
CMAJ Open. 2018 Feb 5;6(1):E63-E70. doi: 10.9778/cmajo.20180008.
4
The increasing inefficiency of private health insurance in Canada.加拿大私人医疗保险效率日益低下。
CMAJ. 2014 Sep 2;186(12):E470-4. doi: 10.1503/cmaj.130913. Epub 2014 Mar 24.
5
Lessons for a national pharmaceuticals strategy in Canada from Australia and New Zealand.澳大利亚和新西兰给加拿大国家药品战略带来的经验教训。
Can J Cardiol. 2007 Jul;23(9):711-8. doi: 10.1016/s0828-282x(07)70815-2.
6
Is PHARMAC's sole-supply tendering policy harming the health of New Zealanders?
N Z Med J. 2005 May 6;118(1214):U1433.
7
The impact of new drug launches on longevity: evidence from longitudinal, disease-level data from 52 countries, 1982-2001.新药上市对寿命的影响:来自1982年至2001年52个国家纵向疾病层面数据的证据。
Int J Health Care Finance Econ. 2005 Mar;5(1):47-73. doi: 10.1007/s10754-005-6601-7.
8
The sorry saga of the statins in New Zealand--pharmacopolitics versus patient care.
N Z Med J. 2003 Mar 14;116(1170):U360.